Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility

Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF). This study aimed to evaluate the incidence, timeline, risk factors, and reversibil...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Medical Journals Sweden 2025-04-01
Reeks:	Acta Oncologica
Onderwerpen:	BRAF/MEK inhibition cardiotoxicity malignant melanoma echocardiography multigated acquisition scan oncocardiology
Online toegang:	https://medicaljournalssweden.se/actaoncologica/article/view/42567
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!